Dyne Therapeutics Inc. has entered into a First Amendment to its existing Loan and Security Agreement with Hercules Capital, Inc. and other lenders, allowing the company to borrow a second term loan tranche of $50 million as of December 8, 2025. The amended agreement also provides Dyne with access to two additional term loan tranches totaling up to $75 million, contingent on meeting specified clinical, regulatory, and commercial milestones. An additional final tranche of up to $50 million may be available, subject to lender approval. The loan bears interest at the Wall Street Journal prime rate plus 2.45%, with a floor of 7.50%, and matures on July 1, 2030. Dyne may make interest-only payments until July 1, 2028, with the possibility of extending this period upon achievement of certain milestones. The company has granted a first-priority security interest in substantially all of its assets as collateral for the loan.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-311221), on December 08, 2025, and is solely responsible for the information contained therein.
Comments